FC
PMCB icon

Financial Consulate’s PharmaCyte Biotech PMCB Stock Holding History

Financial Consulate’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Hold
2
– – ﹤0.01% 1448
2026
Q1 		$2 Hold
2
– – ﹤0.01% 1401
2025
Q4 		$2 Hold
2
– – ﹤0.01% 1338
2025
Q3 		$2 Buy
+2
New +$2 ﹤0.01% 1151

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Financial Consulate's PMCB Position: Q2 2026 in Review

Financial Consulate held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #1448.

Financial Consulate first reported a position in PMCB in Q3 2025 and has held it in 4 quarters since. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Financial Consulate held 2 shares of PharmaCyte Biotech worth $2 as of Q2 2026.
  • Financial Consulate left its PharmaCyte Biotech share count unchanged in Q2 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1448 holding.
  • Financial Consulate first reported a position in PharmaCyte Biotech in Q3 2025 and has held it in 4 quarters since.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.